How reliable is an undetectable viral load?

HIV Medicine

Volumn 10, Issue 8, 2009, Pages 470-476

  Combescure, Christophe ^a   Vallier, N ^a   Ledergerber, B ^b   Cavassini, M ^c   Furrer, H ^d   Rauch, A ^d   Battegay, M ^e   Bernasconi, E ^f   Vernazza, P ^g   Hirschel, B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Adherence; Compliance; Contagiousness; HAART; Reliability; Viral load

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RELIABILITY; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SWITZERLAND; VIRAL LOAD; VIREMIA;

EID: 68449100510     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00714.x     Document Type: Article

References (19)

1. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle [HIV-infected patients under HAART without any other sexually transmitted infection do not transmit HIV by sexual intercourse]. Bull Med Suisses 2008; 89: 165-169.
2. Ledergerber B, von Overbeck J, Egger M, Lüthy R, Swiss HIV Cohort Study (SHCS). The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics. Soz Präventivmed 1994; 39: 387-394.
3. Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921-929.
4. Garcia PM, Kalish LA, Pitt J et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341: 394-402.
5. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196: 1773-1778.
6. Di Mascio M, Markowitz M, Louie M et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic vs. acute and early human immunodeficiency virus type 1 infection. J Virol 2004; 78: 10566-10573.
7. Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS. Modeling the long-term control of viremia in HIV-1-infected patients treated with antiretroviral therapy. Math Biosci 2004; 188: 47-62.
8. Di Mascio M, Markowitz M, Louie M et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77: 12165-12172.
9. Mira JA, Macias J, Nogales C et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002; 7: 251-256.
10. Havlir DV, Bassett R, Levitan D et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286: 171-179.
11. Sklar PA, Ward DJ, Baker RK et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002; 16: 2035-2041.
12. Di Giambenedetto S, Bracciale L, Colafigli M et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: A clinical cohort study. Antivir Ther 2007; 12: 835-839.
13. Novak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40: 468-474.
14. Descamps D, Calvez V, Izopet J et al. Prevalence of resistance mutations in antiretroviral-naïve chronically HIV-infected patients in 1998: a French nationwide study. AIDS 2001; 15: 1777-1782.
15. Soriano V. Prevalence of drug resistance mutations in Spain among both naïve and pretreated patients. Antivir Ther 1999; 4: S57-S63.
16. Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy. AIDS 1996; 10: 625-633.
17. Nettles RE, Kieffer TL, Kwon P et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-829.
18. Raboud JM, Rae S, Woods R et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002; 16: 1627-1632.
19. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41: 1326-1332.